• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种从人全血中纯化血小板活化因子(PAF)的新方法及其灵敏的生物测定法。

A new method of purification and sensitive bioassay of platelet-activating factor (PAF) in human whole blood.

作者信息

Shinozaki K, Kawasaki T, Kambayashi J, Sakon M, Shiba E, Uemura Y, Ou M, Iwamoto N, Mori T

机构信息

Department of Surgery II, Osaka University Medical School, Japan.

出版信息

Life Sci. 1994;54(6):429-37. doi: 10.1016/0024-3205(94)00701-2.

DOI:10.1016/0024-3205(94)00701-2
PMID:8295490
Abstract

There is no satisfactory assay procedure of PAF in human whole blood in terms of sensitivity, reproducibility and simplicity. This is due to coexisting lipids from plasma and cellular membranes which inhibit measurement of PAF in various assay procedures, including bioassay. In the present study, an attempt was made to eliminate these interfering lipid inhibitors from blood samples. Lipids in human whole blood were extracted according to the method of Bligh & Dyer and the organic layer was dried under a stream of nitrogen. Then, the dried organic layer was dissolved in diethyl-ether and the solution was kept at -20 degrees C which was then centrifuged. The resulting supernatant was then applied to an anion-exchange column and the PAF fraction was obtained by step-wise gradient elution. The fraction was further purified by normal phase HPLC. Then PAF in the final sample was determined by sensitive bioassay using rabbit platelets containing fibrinogen and epinephrine. The recovery rate of PAF throughout this procedure was constant and satisfactory (37.4 +/- 9.7%), which was confirmed using [3H]-PAF. The lower limit of the present assay was estimated to be 5pg in 1 ml of blood and it was sensitive enough to detect PAF in blood samples from healthy volunteers and patients with sepsis or liver cirrhosis. Furthermore, attempts were made to compare the sensitivity and the recovery of our method with these of a commercially available radioimmunoassay (RIA) kit for PAF. However, it was not possible to detect any amount of authentic PAF added to whole blood.

摘要

就敏感性、可重复性和简便性而言,目前尚无令人满意的人全血中血小板活化因子(PAF)的检测方法。这是由于血浆和细胞膜中存在的共存脂质会在包括生物测定在内的各种检测方法中抑制PAF的测量。在本研究中,试图从血液样本中消除这些干扰性脂质抑制剂。按照布莱和戴尔的方法提取人全血中的脂质,有机层在氮气流下干燥。然后,将干燥的有机层溶解在乙醚中,溶液保存在-20℃,随后进行离心。所得上清液应用于阴离子交换柱,通过逐步梯度洗脱获得PAF馏分。该馏分通过正相高效液相色谱进一步纯化。然后,使用含有纤维蛋白原和肾上腺素的兔血小板通过灵敏的生物测定法测定最终样品中的PAF。使用[3H]-PAF证实,整个过程中PAF的回收率恒定且令人满意(37.4±9.7%)。本检测方法的下限估计为每1毫升血液中5皮克,灵敏度足以检测健康志愿者以及脓毒症或肝硬化患者血液样本中的PAF。此外,还尝试将我们方法的灵敏度和回收率与市售的PAF放射免疫分析(RIA)试剂盒的灵敏度和回收率进行比较。然而,无法检测到添加到全血中的任何量的纯PAF。

相似文献

1
A new method of purification and sensitive bioassay of platelet-activating factor (PAF) in human whole blood.一种从人全血中纯化血小板活化因子(PAF)的新方法及其灵敏的生物测定法。
Life Sci. 1994;54(6):429-37. doi: 10.1016/0024-3205(94)00701-2.
2
Development of a sensitive and specific 14C-serotonin release assay for platelet-activating factor (PAF) in human neutrophils.用于检测人中性粒细胞中血小板活化因子(PAF)的灵敏且特异的14C-血清素释放测定法的开发。
J Lipid Mediat. 1990 Nov-Dec;2(6):329-41.
3
Simple and rapid measurement of platelet-activating factor (PAF) in whole blood.
Biochem Int. 1991 Jul;24(5):823-31.
4
Comparison of a radioimmunoassay and bioassay for embryo-derived platelet-activating factor.胚胎源性血小板活化因子放射免疫分析与生物测定的比较
Hum Reprod. 1991 Jul;6(6):872-8. doi: 10.1093/oxfordjournals.humrep.a137443.
5
Stability of platelet activating factor (PAF) in human saliva. Quantitation by radioimmunoassay.血小板活化因子(PAF)在人唾液中的稳定性。通过放射免疫测定法定量。
Clin Chim Acta. 1991 Aug 30;200(2-3):161-73. doi: 10.1016/0009-8981(91)90087-s.
6
Quantitative analysis of platelet-activating factor in human plasma. Application to patients with liver cirrhosis and disseminated intravascular coagulation.
J Immunol Methods. 1993 Dec 3;166(2):251-61. doi: 10.1016/0022-1759(93)90366-f.
7
Quantitation by radioimmunoassay of PAF in human saliva.
Lipids. 1991 Dec;26(12):1140-3. doi: 10.1007/BF02536518.
8
The human platelet as a reproducible and sensitive cell for the detection and assay of platelet-activating factor.人血小板作为检测和测定血小板活化因子的可重复性和敏感细胞。
Anal Biochem. 1992 Jul;204(1):79-84. doi: 10.1016/0003-2697(92)90142-t.
9
Inhibitor(s) of platelet-activating factor (PAF) in human saliva.人唾液中血小板活化因子(PAF)的抑制剂
Lipids. 1991 Dec;26(12):1144-7. doi: 10.1007/BF02536519.
10
A specific, sensitive and high-capacity immunoassay for PAF.
Lipids. 1991 Dec;26(12):1136-9. doi: 10.1007/BF02536517.

引用本文的文献

1
Platelet-activating factor receptor-mediated PI3K/AKT activation contributes to the malignant development of esophageal squamous cell carcinoma.血小板激活因子受体介导的 PI3K/AKT 激活促进食管鳞状细胞癌的恶性发展。
Oncogene. 2015 Oct 1;34(40):5114-27. doi: 10.1038/onc.2014.434. Epub 2015 Feb 2.
2
Hepatic stellate cells may be potential effectors of platelet activating factor induced portal hypertension.肝星状细胞可能是血小板活化因子诱导门静脉高压的潜在效应细胞。
World J Gastroenterol. 2008 Jan 14;14(2):218-23. doi: 10.3748/wjg.14.218.
3
Effect of increased hepatic platelet activating factor and its receptor portal hypertension in CCl4-induced liver cirrhosis.
肝内血小板活化因子及其受体增加对四氯化碳诱导的肝硬化门静脉高压的影响。
World J Gastroenterol. 2006 Feb 7;12(5):709-15. doi: 10.3748/wjg.v12.i5.709.
4
Increased hepatic platelet activating factor (PAF) and PAF receptors in carbon tetrachloride induced liver cirrhosis.四氯化碳诱导的肝硬化中肝血小板活化因子(PAF)及PAF受体增加。
Gut. 2004 Jun;53(6):877-83. doi: 10.1136/gut.2003.024893.
5
Platelet-activating factor and P-selectin activities in thrombotic and nonthrombotic Behçet's patients.血栓形成和非血栓形成的白塞病患者的血小板活化因子和P-选择素活性
Rheumatol Int. 2005 Jun;25(5):326-31. doi: 10.1007/s00296-004-0450-4. Epub 2004 Mar 5.